Compare CIB & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIB | BBIO |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 14.7B |
| IPO Year | 1995 | 2019 |
| Metric | CIB | BBIO |
|---|---|---|
| Price | $65.18 | $75.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | $47.75 | ★ $76.24 |
| AVG Volume (30 Days) | 295.3K | ★ 1.8M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ 22.14 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $6,289,868,892.00 | $353,780,000.00 |
| Revenue This Year | $33.27 | $127.64 |
| Revenue Next Year | $7.26 | $78.38 |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | 15.25 | ★ 62.46 |
| 52 Week Low | $31.19 | $27.23 |
| 52 Week High | $65.73 | $78.44 |
| Indicator | CIB | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 62.87 |
| Support Level | $62.30 | $75.82 |
| Resistance Level | $63.39 | $78.44 |
| Average True Range (ATR) | 1.37 | 2.20 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 87.50 | 68.91 |
Grupo Cibest SA formerly BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala. The Bank has the following segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking and All other segments. The majority of revenue is generated from the Banking Colombia segment.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.